Product Description
Blood Group Antigen H Type 2 Antibody [19-OLE] | 33-374 | ProSci
Host: Mouse
Reactivity: Human
Homology: N/A
Immunogen: Mucinous colonic adenocarcinoma was used as the immunogen for the ABO antibody.
Research Area: Other
Tested Application: IF, IHC-P
Application: Immunofluorescence: 0.5-1 ug/ml
Immunohistochemistry (FFPE) : 0.5-1 ug/ml for 30 min at RT (1)
Optimal dilution of the ABO antibody should be determined by the researcher.
1. Staining of formalin-fixed tissues requires boiling tissue sections in 10mM Citrate buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 min
Specificiy: N/A
Positive Control 1: N/A
Positive Control 2: N/A
Positive Control 3: N/A
Positive Control 4: N/A
Positive Control 5: N/A
Positive Control 6: N/A
Molecular Weight: N/A
Validation: N/A
Isoform: N/A
Purification: PEG precipitation
Clonality: Monoclonal
Clone: 19-OLE
Isotype: IgM, kappa
Conjugate: Unconjugated
Physical State: Liquid
Buffer: PBS with 0.1 mg/ml BSA and 0.05% sodium azide
Concentration: 0.2 mg/mL
Storage Condition: Aliquot and Store at 2-8˚C. Avoid freez-thaw cycles.
Alternate Name: Histo-blood group ABO system transferase, Fucosylglycoprotein 3-alpha-galactosyltransferase, Fucosylglycoprotein alpha-N-acetylgalactosaminyltransferase, Glycoprotein-fucosylgalactoside alpha-N-acetylgalactosaminyltransferase, Glycoprotein-fucosylgalactoside alpha-galactosyltransferase, Histo-blood group A transferase, A transferase, Histo-blood group B transferase, B transferase, NAGAT, Fucosylglycoprotein alpha-N-acetylgalactosaminyltransferase soluble form, ABO
User Note: Optimal dilutions for each application to be determined by the researcher
BACKGROUND: Recognizes the blood group H type 2 antigens, trisaccharide Fuc (a1-2) Gal (b1-4) GlcNAc (b1) of human origin. This protein is the basis of the ABO blood group system. The histo-blood group ABO involves three carbohydrate antigens: A, B, and H. A, B, and AB individuals express a glycosyltransferase activity that converts the H antigen to the A antigen (by addition of UDP-GalNAc) or to the B antigen (by addition of UDP-Gal) , whereas O individuals lack such activity. It is expressed on endothelial cells, epithelial cells and granulocytes. Increased expression of this antigen has been observed on some tumor tissues such as gastric carcinomas, urothelial carcinomas, and colon carcinomas.